Ultrapotent, broadly neutralizing and long-acting
anti-SARS-CoV-2 mAbs for the prevention of
COVID-19 infection in immunocompromised patients

MISSION

 

  • SpikImm was founded in 2021 by Truffle Capital and the Institut Pasteur to develop human monoclonal antibodies (mAbs) to prevent COVID-19.
  • SPK001 and SPK002, SpikImm‘s lead candidates, originally developed in the laboratory of Humoral Immunology (Institut Pasteur & Inserm) headed by Dr Hugo MOUQUET, have demonstrated a potent and broad neutralization activity in vitro against SARS-CoV-2 and variants of concern, as well as a therapeutic efficacy in vivo in mouse and hamster models.
  • Results have been published in June 2022 in Journal of Experimental Medicine (JEM).
  • SPK001 and SPK002 are developed as a long-acting antibody with a convenient, intramuscular administration for the prevention of COVID-19 (pre-exposure prophylaxis) in immunocompromised patients unable to mount a protective antibody response after vaccination.
  • SpikImm has recently dosed the first subject in a phase 1 clinical trial of SPK001. SpikImm then expects to demonstrate the medical benefit in a phase 2 in immunocompromised patients. Depending on the results, SPK001 may seek Emergency Use Authorization (EUA) as from Q2 2023.

TEAM

MANAGEMENT

Antoine Pau, PharmD

Antoine Pau, PharmD

CEO

Dr. Catherine Combot-Plétan

Dr. Catherine Combot-Plétan

Chief Development Officer

Pr. Karine Lacombe

Pr. Karine Lacombe

Chief Medical Officer

Dr. Hélène Sicard

Dr. Hélène Sicard

Preclinical expert

Dr. Jérôme Tiollier

Dr. Jérôme Tiollier

CMC expert

INVENTOR & CHIEF SCIENTIFIC OFFICER

Dr. Hugo Mouquet

Dr. Hugo Mouquet

BOARD OF DIRECTORS

Dr. Philippe Pouletty

Dr. Philippe Pouletty

Chairman

Pr. Jorge Kalil

Pr. Jorge Kalil

Pr. Hartmut J. Ehrlich

Pr. Hartmut J. Ehrlich

SCIENCE

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

MEDIA

Preview of Washington Post article by Mark Johnson on Novembre 21, 2022

Washington Post, Novembre 2022

PR April 2022

Press release April 2022

Nature.com

france 2030

Press release France 2030

Businesswire.com